Big pharma "needs to play ball" after US gov't backs AIDS patent pool
This article was originally published in SRA
Executive Summary
The US government has come out with its strongest support yet for the AIDS medicines patent pool initiative, increasing the pressure on pharmaceutical companies to license their patent rights to the pool so that generic firms can make affordable fixed-dose combination antiretrovirals for developing countries1.